Myeloma Crowd Radio: Drs. Anja Seckinger and Dirk Hose, University of Heidelberg
Play • 1 hr 2 min
Many patients are familiar with the monoclonal antibodies daratumumab and elotuzumab. These target a specific protein on the surface of myeloma cells. A new approach is in progress to target both a protein on the surface of myeloma cells (BCMA) while also activating the immune system's T cells. This is called a bi-specific antibody, going after two targets at the same time. Join us to learn more about this fascinating approach from German researchers Anja Seckinger, MD and Dirk Hose, MD of the University of Heidelberg. This could provide an off-the-shelf immunotherapy for myeloma patients that gives myeloma a double punch. 

Special thanks to our episode sponsor, Takeda Oncology.
More episodes
Clear search
Close search
Google apps
Main menu